Shine Investment Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shine Investment Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$14K	Sell	190 -493	-72%	-$49.9K	﹤0.01%	496
2020 Q2	$84K	Buy	683 +81	+13%	+$8.05K	0.03%	217
2020 Q1	$51K	Buy	602 +401	+200%	+$34.6K	0.02%	263
2019 Q4	$17K	Buy	+201	New	+$15.2K	0.01%	494
2019 Q3	–	Sell	-194	Closed	-$17K	–	722
2019 Q2	$17K	Buy	194 +61	+46%	+$5.22K	0.01%	473
2019 Q1	$12K	Buy	133 +13	+11%	+$1.21K	0.01%	519
2018 Q4	$10K	Buy	120 +20	+20%	+$1.9K	﹤0.01%	518
2018 Q3	$10K	Buy	+100	New	+$9.98K	0.01%	513

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Shine Investment Advisory Services's BMRN Position: Q3 2020 in Review

Shine Investment Advisory Services reduced its BioMarin Pharmaceuticals (BMRN) stake by 72% in Q3 2020, selling an estimated $49.9K and leaving 190 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

Shine Investment Advisory Services first reported a position in BMRN in Q3 2018 and has held it in 8 quarters since. The position peaked at $84K in Q2 2020. 497 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Shine Investment Advisory Services held 190 shares of BioMarin Pharmaceuticals worth $14K as of Q3 2020.
Shine Investment Advisory Services sold 493 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $49.9K.
BioMarin Pharmaceuticals made up ﹤0.01% of Shine Investment Advisory Services's portfolio in Q3 2020, its #496 holding.
Shine Investment Advisory Services first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 8 quarters since.
Shine Investment Advisory Services's BioMarin Pharmaceuticals position peaked at $84K in Q2 2020.
497 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Shine Investment Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.